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SCIENTIFIC EDITORIAL
Should angiotensin-converting enzyme inhibitors be
used in all patients with coronary artery disease or
restricted to those with a history of myocardial
infarction or myocardial revascularization?
Faut-il prescrire des IEC chez tous les coronariens ou restreindre leur
utilisation aux patients ayant des antécédents d’infarctus ou de
revascularisation myocardique ?
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Everyone agrees that angiotensin-converting enzyme (ACE) inhibitors should be used in
patients with coronary artery disease and either left ventricular dysfunction or a history
of heart failure [1]. In contrast, whether they should be prescribed in all patients with
coronary artery disease when they have preserved left ventricular function is debated.
The most recent guidelines [2,3] advocate the use of ACE-inhibitors for patients with no
left ventricular dysfunction when they have concomitant conditions such as hypertension
or diabetes (class IA). The recommendation is less strong, however, when these patients
have no such concomitant conditions (class IIa). The basis for these recommendations is
derived from cost/beneﬁts analyses, and from subgroup analyses such as the one presented
here by Bertrand et al. [4].
In their analysis from the European trial on reduction of cardiac events with perindopril
in stable coronary artery disease (Europa) data, Bertrand et al. [4] show that treat-Inhibiteurs de
l’enzymede conversion ;
Études randomisées ;
Analyse de sous-groupe
ment with perindopril 8mg resulted in a consistent reduction in the primary endpoint
of the trial (cardiovascular mortality, acute myocardial infarction or resuscitated car-
diac arrest), both for patients with previous myocardial infarction (risk reduction of
22%) and for those with a history of myocardial revascularization (risk reduction of
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Likewise, in the Hope trial [6], there was absolutely no dif-2
7%). Speciﬁcally, the occurrence of myocardial infarction
as reduced signiﬁcantly in both populations, as was the
ccurrence of heart failure, another secondary endpoint of
he trial. Moreover, the results were consistent according
o risk factor subgroups (patients with or without hyperten-
ion, diabetes mellitus or hypercholesterolemia), as it was
n patients with or without lipid-lowering and antiplatelet
edications at baseline.
Overall, these results are hardly surprising, as risk reduc-
ion for the primary endpoint in the Europa trial was 20%,
nd patients with a history of either myocardial infarction
r myocardial revascularization comprised 90% of the total
rial population [5].
The real question raised by the present analysis, how-
ver, goes beyond the results presented here and is the
ollowing: do these results actually mean that the beneﬁt
f ACE-inhibitors in patients with stable coronary artery dis-
ase who have no evidence of left ventricular dysfunction
s conﬁned to those with a history of myocardial infarction
nd/or a history of myocardial revascularization? A posi-
ive answer to this question would obviously justify the
urrent recommendations which consider that, when left
igure 1. Updated meta-analysis of the long-term trials comparing ACE
eart failure or left ventricular dysfunction. Abbreviations: CV = cardiova
f
w
m
vN. Danchin
entricular function is not impaired, ACE-inhibitor treat-
ent is mandatory in patients with associated conditions
nly.
A detailed analysis of the data available from the Europa
rial [5], but also from the Heart outcomes prevention
valuation (Hope) trial [6], however, does not warrant
uch a conclusion. To convincingly restrict the beneﬁts of
CE-inhibitor therapy to patients with previous myocardial
nfarction or revascularization would mean that patients
eeting none of these criteria would behave differently
ompared with those who did. This is clearly not the case. In
he Europa trial [5], the magnitude of the beneﬁt of perindo-
ril treatment was somewhat greater in patients without a
istory of myocardial revascularization compared with those
ith such a history, while, though slightly less, the magni-
ude of the effect was not signiﬁcantly different in patients
ith or without a history of previous myocardial infarction.-inhibitors and placebo in coronary artery disease patients without
scular; MI =myocardial infarction.
erence in the favorable effect of ramipril, when patients
ere categorized among those with or without a history of
yocardial infarction. In the combined analysis of the indi-
idual data from the Europa and Hope trials, there was even
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Table 1 Meta-analysis of randomized, controlled trials comparing long-term treatment with ACE-inhibitors or placebo
in patients with stable coronary artery disease and no heart failure or left ventricular dysfunction. The trials include the
36,513 patients having participated in all seven trials included in reference [9] and those who participated in the Imagine
trial.
Event Relative risk (ﬁxed model) 95% conﬁdence interval p value
All-cause death 0.87 0.81—0.94 < 0.001
Cardiovascular death 0.83 0.75—0.91 < 0.001
Myocardial infarction 0.83 0.77—0.90 < 0.001
Stroke 0.78 0.68—0.89 < 0.001
Cardiac arrest 0.61 0.43—0.87 < 0.001
Heart failure 0.78 0.68—0.895 < 0.001
RUnstable angina 0.98
Myocardial revascularization 0.94
a trend to a greater beneﬁt in patients without a history
of myocardial revascularization (p for interaction = 0.078)
[7].
These observations emphasize the limitations of sub-
group analyses from large, randomized trials. Presenting
positive results in speciﬁc subgroups from a trial that
documents positive results in the whole population may
falsely hint at a lack of efﬁcacy of the medication stud-
ied in the other subgroups. Indeed, subgroup analyses are
exploratory only and, whether positive or negative, can-
not be considered deﬁnite proof of the efﬁcacy of a given
medication (or lack thereof). In the present case, the feel-
ing left by reading the paper by Bertrand et al. [4] might
wrongly be that the beneﬁts of perindopril do not exist in
other populations than those assessed here. In fact, three
meta-analyses of long-term trials of patients with stable
coronary artery disease without heart failure or left ven-
tricular dysfunction show that this should not be the case
[7—9]. All three found a positive effect of these medi-
cations on cardiovascular mortality, myocardial infarction
and stroke; in addition, myocardial revascularization, heart
failure and new onset diabetes mellitus are signiﬁcantly
decreased. Additionally, and importantly, all-cause mor-
tality is also signiﬁcantly decreased by 14%. Adding the
recently published results of the Ischemia management with
accupril post bypass graft via inhibition of the convert-
ing enzyme (Imagine) trial [10], which showed no beneﬁt
of the early and prolonged treatment with quinapril in
patients undergoing coronary artery bypass surgery, does not
substantially change the conclusions of the meta-analysis
(Fig. 1, Table 1).
In summary, there is convincing evidence of the efﬁ-
cacy of ACE-inhibitor therapy in patients with coronary
artery disease, even when left ventricular dysfunction,
previous myocardial infarction or previous myocardial revas-
cularization are absent. This simple message should not
be blurred by the present subgroup study from Bertrand
et al.Disclosures
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eferences
[1] Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines
for the diagnosis and treatment of acute and chronic heart
failure 2008: the Task force for the diagnosis and treatment of
acute and chronic heart failure 2008 of the European society of
cardiology. Developed in collaboration with the Heart failure
association of the ESC (HFA) and endorsed by the European
society of intensive care medicine (ESICM). Eur J Heart Fail
2008;10:933—89.
[2] Fox K, Garcia MA, Ardissino D, et al. Guidelines on the man-
agement of stable angina pectoris: executive summary: the
Task force on the management of stable angina pectoris of the
european society of cardiology. Eur Heart J 2006;27:1341—81.
[3] Van de Werf F, Bax J, Betriu A, et al. Management of acute
myocardial infarction in patients presenting with persistent ST-
segment elevation: the task force on the management of st-
segment elevation acute myocardial infarction of the european
society of cardiology. Eur Heart J 2008;29:2909—45.
[4] Bertrand ME FK, Remme WJ, Ferrari R, Simoons ML.
Angiotensin-converting enzyme inhibition with perindopril in
patients with prior myocardial infarction and/or revasculariza-
tion: a subgroup analysis of the Europa trial. Arch Cardiovasc
Dis 2009.
[5] Fox KM. Efﬁcacy of perindopril in reduction of cardiovascular
events among patients with stable coronary artery disease: ran-
domised, double-blind, placebo-controlled, multicentre trial
(the Europa study). Lancet 2003;362:782—8.
[6] Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-
converting enzyme inhibitor, ramipril, on cardiovascular events
in high-risk patients. The Heart outcomes prevention evalua-
tion study investigators. N Engl J Med 2000;342:145—53.
[7] Dagenais GR, Pogue J, Fox K, et al. Angiotensin-converting
enzyme inhibitors in stable vascular disease without left ven-
tricular systolic dysfunction or heart failure: a combined
analysis of three trials. Lancet 2006;368:581—8.
[8] Al-Mallah MH, Tleyjeh IM, Abdel-Latif AA, et al. Angiotensin-
converting enzyme inhibitors in coronary artery disease and
preserved left ventricular systolic function: a systematic
review and meta-analysis of randomized controlled trials. J
Am Coll Cardiol 2006;47:1576—83.
[9] Danchin N, Cucherat M, Thuillez C, et al. Angiotensin-
converting enzyme inhibitors in patients with coronary artery
disease and absence of heart failure or left ventricular systolic
dysfunction: an overview of long-term randomized controlled
trials. Arch Intern Med 2006;166:787—96.
10] Rouleau JL, Warnica WJ, Baillot R, et al. Effects of angiotensin-
converting enzyme inhibition in low-risk patients early after
coronary artery bypass surgery. Circulation 2008;117:24—31.
